Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,460 across all filing types
Latest filing 2025-04-22 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
董事会审计委员会工作细则（2025年4月）
Governance Information Classification · 95% confidence The document is titled as the 'Board Audit Committee Working Rules' of a company, detailing the structure, responsibilities, composition, and procedures of the audit committee within the board of directors. It references relevant laws and regulations but does not contain financial statements, audit results, or report data. It is a governance document outlining internal rules and committee operations rather than an audit report or annual report. Therefore, it fits best under Governance Information (CGR). The document length is under 5,000 characters, but it is a substantive governance document, not a mere announcement or certification, so it is not RPA or RNS.
2025-04-22 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2024" for Huabang Life Health Co., Ltd. It details the independent director's activities, attendance at board and committee meetings, opinions on company matters, and oversight of audits and governance. The content focuses on the director's duties, governance, and supervisory roles rather than presenting financial statements or audit results themselves. It is a detailed report on board/management activities and governance oversight rather than a full annual report, audit report, or financial statement. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities. The document is not a financial report or audit report but a management-related report by an independent director.
2025-04-22 Chinese
独立董事提名人声明与承诺（刘忠海）
Board/Management Information Classification · 95% confidence The document is a formal statement and commitment by the nominator regarding the nomination of an independent director candidate for the company's board. It includes detailed declarations about the nominee's qualifications, compliance with relevant laws and regulations, and independence criteria. There are no financial statements, earnings data, or report summaries. The document is a regulatory disclosure related to board nomination and compliance, not a financial report or meeting material. It fits best under Board/Management Information (MANG) as it concerns board member nomination and related declarations.
2025-04-22 Chinese
关于召开2024年度暨2025年第一季度业绩网上说明会的公告
Investor Presentation Classification · 85% confidence The document is an announcement about a scheduled online earnings presentation (业绩网上说明会) for the 2024 annual and 2025 first quarter results. It references that the 2024 annual report and 2025 Q1 report have already been disclosed on the company's information disclosure website. The document invites investors to participate in the online earnings explanation meeting and to submit questions in advance. The content is primarily an invitation and announcement of the earnings call event, not the actual earnings release or detailed financial report itself. Therefore, this document fits best as a Call Transcript (CT) announcement or an Investor Presentation (IP) announcement. However, since it is announcing the earnings explanation meeting (which is a form of investor presentation focused on financial results and company performance), the most appropriate classification is Investor Presentation (IP). The document length is short and it is not the transcript itself, but an announcement of the event. Given the content and context, confidence is high but not absolute since it is an announcement rather than the presentation itself.
2025-04-22 Chinese
独立董事提名人声明与承诺（黎明）
Board/Management Information Classification · 95% confidence The document is a detailed statement and commitment by the nominator regarding the nomination of an independent director candidate for the company's board. It includes declarations about the candidate's qualifications, compliance with relevant laws and regulations, and independence criteria. There is no financial data, no report of financial performance, no voting results, no meeting materials, and no announcement of a report publication. The content is focused on board/management information specifically about director nomination and related compliance. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 4303 characters, which is sufficient for a detailed statement but not a full report. Hence, the classification is MANG with high confidence.
2025-04-22 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 23rd meeting of the 8th Board of Directors of Huabang Life Health Co., Ltd. It includes approvals of various reports and proposals such as the 2024 General Manager Work Report, 2024 Board Work Report, 2024 Financial Final Accounts Report, 2024 Profit Distribution Plan, 2024 Annual Report and its summary, 2025 Q1 Report, internal control self-evaluation report, audit institution renewal, asset impairment provisions, accounting policy changes, financial assistance and guarantees, valuation improvement plan, and amendments to company governance documents. It also covers board member elections and remuneration plans. The document repeatedly states that these reports and proposals will be submitted to the 2024 Annual General Meeting (AGM) for approval and that the full reports are published separately on the official disclosure website (cninfo.com.cn) and newspapers. The document itself is a formal board meeting resolution announcement, not the reports themselves. It is a regulatory announcement of board decisions and upcoming shareholder meeting agenda items, including governance and management changes. Therefore, the best fitting classification is Board/Management Information (MANG). The document length (5666 characters) and content confirm it is not a full financial report or an earnings release but a board meeting resolution announcement.
2025-04-22 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.